Fig. 2
The mechanisms of novel antidiabetic drugs in diabetic HFpEF via inflammation, oxidative stress and lipotoxicity. Novel antidiabetic drugs could reduce inflammation, oxidative stress, apoptosis and lipotoxicity, by activating several signaling pathways, including AMPK/mTOR, AMPK/PGC-1α, Sirt1/AMPK, or by inhibiting certain signaling pathways, such as JAK/STAT, RhoA/ROCK, mTOR/HIF-1α and ROCK/PPARα pathway, ultimately improving diabetic HFpEF